Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14611633 | 1.00 | GRM5 (0.52) | GRM5CYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL5488717 | 0.94 | GRM5 (0.53) | GRM5CYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL5478827 | 0.94 | GRM5 (0.53) | GRM5CYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL14088779 | 0.88 | GRM5 (0.47) | GRM5MEN1KMT2AMAPT | |
| SCHEMBL4663256 | 0.86 | GRM5 (0.45) | GRM5KMT2AKDM4E | |
| SCHEMBL5485386 | 0.84 | GRM5 (0.55) | GRM5CYP3A4 | |
| SCHEMBL5487679 | 0.84 | GRM5 (0.55) | GRM5CYP3A4 | |
| SCHEMBL4661655 | 0.80 | GRM5 (0.43) | GRM5CYP3A4MEN1KMT2AKDM4E | |
| SCHEMBL4660532 | 0.80 | GRM5 (0.43) | GRM5CYP3A4MEN1KMT2AKDM4E | |
| SCHEMBL4663129 | 0.76 | GRM5 (0.41) | GRM5CYP3A4MEN1KMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | claimed |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | GRM1, GRM5, GRIN1 | GRM5 2/4885CYP3A4 3882/4885MEN1 2987/4885 |
| US-20080194571-A1 | Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM1, GRM5, GRIN1 | GRM5 2/4885CYP3A4 3882/4885MEN1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.